Reynders McVeigh Capital Management LLC Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Reynders McVeigh Capital Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 101,375 shares of the company’s stock after selling 6,749 shares during the period. Reynders McVeigh Capital Management LLC’s holdings in Johnson & Johnson were worth $17,908,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Nordwand Advisors LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $785,273,000. Savant Capital LLC boosted its holdings in Johnson & Johnson by 8,568.8% in the fourth quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after purchasing an additional 3,588,251 shares during the period. Edmp Inc. boosted its holdings in Johnson & Johnson by 17,222.9% in the fourth quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after purchasing an additional 3,204,658 shares during the period. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. Finally, GQG Partners LLC boosted its holdings in Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the period. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $154.41 on Friday. The company’s 50-day moving average price is $159.89 and its two-hundred day moving average price is $165.86. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The stock has a market cap of $401.27 billion, a PE ratio of 32.30, a price-to-earnings-growth ratio of 2.67 and a beta of 0.53. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.67 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.08%. The ex-dividend date is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is presently 99.58%.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on JNJ shares. Guggenheim started coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Atlantic Securities reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Piper Sandler reduced their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, UBS Group assumed coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target for the company. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.